MiR-708 targets IKKβ, a kinase that induces NF-κB signaling, leading to the inhibition of the NF-κB pathway in chronic lymphocytic leukemia [87]. This evidence concerns the gene NFKB1 and B-cell chronic lymphocytic leukemia.